M&A / Deals Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers BioPharma DiveEquipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.M&A / DealsImmunology & InflammationRead full story pharminent April 15, 2026 (Last updated: April 16, 2026) BioPharma Dive Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases. M&A / DealsImmunology & InflammationRead full story Post navigation Previous: Travere wins long-awaited approval for kidney disease drugNext: Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026